More and more workers are using weight loss drugs. It’s costing their employers a fortune

Large employers are rapidly expanding coverage for GLP-1 weight loss drugs, with 43% of firms over 5,000 employees now offering the benefit, up from 28% last year. This trend is significantly impacting corporate budgets, as many companies report higher-than-expected usage and substantial increases in prescription drug spending, exemplified by drugs like Wegovy with a list price of $1,350 per month. Consequently, some employers are re-evaluating coverage, considering stricter eligibility or increased employee cost-sharing, which is contributing to a 6% rise in average family health insurance premiums to $27,000 this year, signaling a growing financial burden for corporations and a dynamic, evolving market for pharmaceutical and health insurance sectors.

Analysis

Large employers are rapidly increasing coverage for GLP-1 weight loss medications, with 43% of firms over 5,000 employees now offering this benefit, a significant rise from 28% last year. This expansion, driven by the drugs' efficacy and their perceived value in attracting and retaining talent, is creating substantial budgetary pressures, highlighted by the approximately $1,350 per month list price for drugs like Wegovy.

Usage of GLP-1s has exceeded employer expectations, with nearly 60% of large firms reporting higher-than-predicted uptake, leading to a "significant" impact on prescription drug spending for two-thirds of these employers. One firm saw GLP-1s become its top drug expenditure, while a large retailer projected a cost increase from $0.5 million to $1.2 million. Consequently, employers are re-evaluating coverage, considering stricter eligibility criteria or requiring participation in weight management programs.

The escalating costs of GLP-1 drugs are a key contributor to rising health insurance premiums, with average family coverage reaching $27,000 this year, a 6% increase. This trend, alongside other factors like hospital prices, signals a "quiet alarm bell" for employers, potentially leading to increased deductibles and employee cost-sharing. The market for GLP-1 coverage is still evolving, with future price adjustments and expanded indications likely to reshape employer strategies.

Key Decisions for Investors

• Investors should closely monitor the evolving employer coverage policies for GLP-1 drugs, as stricter eligibility or increased cost-sharing could impact patient access and pharmaceutical sales volumes.
• Evaluate potential pricing pressure on GLP-1 manufacturers like Novo Nordisk (NVO), given employer budget constraints and the stated intent of some firms to re-negotiate or limit coverage.
• Consider the implications for the health insurance sector, as rising GLP-1 costs contribute to premium increases and may lead to further shifts in benefit design, impacting profitability and consumer spending.